Indegene Ltd Stock Falls to 52-Week Low of Rs 433.7

Recent Price Movement and Market Context

On 13 Mar 2026, Indegene Ltd’s share price declined by 2.33% to hit an intraday low of Rs 433.7, setting a fresh 52-week low. This marks a continuation of a losing streak, with the stock falling for ten consecutive trading sessions and delivering a negative return of 13.21% over this period. The stock’s performance today lagged behind the healthcare services sector by 1.03%, signalling relative weakness within its industry group.

Technically, Indegene is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring the bearish momentum. This technical positioning aligns with broader market trends, as the Sensex itself has been under pressure, closing 1.21% lower at 75,117.14 points and hovering close to its own 52-week low, which is 4.92% away at 71,425.01 points. The Sensex is also trading below its 50-day moving average, which remains below the 200-day moving average, reflecting a bearish market environment.

Long-Term Performance and Comparative Analysis

Over the past year, Indegene Ltd has recorded a negative return of 16.19%, significantly underperforming the Sensex, which posted a positive return of 1.78% during the same period. The stock has also lagged behind the BSE500 index across multiple time frames, including the last three years, one year, and three months, indicating persistent underperformance relative to a broad market benchmark.

Indegene’s 52-week high was Rs 632.1, highlighting the extent of the decline from its peak to the current low of Rs 433.7. This represents a drop of approximately 31.4% from its highest price in the last year.

Financial Metrics and Growth Trends

Indegene Ltd’s long-term growth has been modest, with net sales increasing at an annualised rate of 13.14% over the past five years. Operating profit has grown at a similar pace of 13.41% annually during the same period. Despite these growth figures, the stock’s price performance has not reflected this steady expansion, as evidenced by its negative returns and declining valuation levels.

In the most recent quarter ending December 2025, the company reported its highest quarterly net sales at Rs 942.10 crores and a peak PBDIT of Rs 159.50 crores. These figures indicate positive momentum in revenue and earnings generation, although this has yet to translate into a sustained improvement in the stock price.

Valuation and Efficiency Indicators

Indegene maintains a strong return on equity (ROE) of 15.56%, reflecting efficient utilisation of shareholder capital. The company’s average debt-to-equity ratio stands at zero, indicating a debt-free capital structure which reduces financial risk. The stock trades at a price-to-book value of 3.7, suggesting a premium valuation relative to its book value and peers’ historical averages.

Despite the premium valuation, the company’s price-to-earnings-to-growth (PEG) ratio is 1.7, which is moderate and indicates that the market is pricing in growth expectations consistent with its earnings expansion of 14.9% over the past year.

Technical Indicators and Market Sentiment

Technical analysis presents a predominantly bearish outlook for Indegene Ltd. The Moving Average Convergence Divergence (MACD) indicator is bearish on the weekly chart, while the monthly chart does not provide a clear signal. The Relative Strength Index (RSI) is bullish on a weekly basis but shows no signal monthly. Bollinger Bands indicate bearish trends on both weekly and monthly timeframes. The daily moving averages are also bearish, reinforcing the downward momentum.

Additional technical tools such as the Know Sure Thing (KST) indicator and Dow Theory both signal bearish trends on the weekly chart, with the monthly Dow Theory also bearish. The On-Balance Volume (OBV) indicator is mildly bearish weekly, with no clear trend monthly, suggesting subdued buying interest.

Summary of Rating and Market Capitalisation

MarketsMOJO assigns Indegene Ltd a Mojo Score of 47.0, categorising it with a Sell grade as of 23 Feb 2026, a downgrade from its previous Hold rating. The company is classified as a small-cap stock within the healthcare services sector. This rating reflects the combination of its recent price weakness, relative underperformance, and valuation considerations.

Overall, Indegene Ltd’s stock has experienced a notable decline to its 52-week low of Rs 433.7, driven by a combination of subdued price momentum, underwhelming relative returns, and technical indicators signalling bearish trends. While the company demonstrates solid financial metrics such as a strong ROE and debt-free balance sheet, these factors have not yet been sufficient to arrest the stock’s downward trajectory in the current market environment.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today